Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Enfortumab Vedotin

Stage Phase 2

Sponsor Memorial Sloan Kettering

Modality antibody-drug conjugate

Class Nectin-4-directed ADC

Target Nectin-4 (NECTIN4)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/study/

ClinicalTrials.gov API v2 records pulled 2026-10-27 (raw/ctgov/; registry fields as entered by sponsors). Search for adenoid cystic carcinoma returned 171 studies; none is an ACC-specific Phase 3. Records read: ACCURACY NCT03691207 (Ayala, completed, n 87, results posted 01.31.2024); CB-103 NCT03422679 (Cellestia, terminated for business reasons, n 79); CB-103 plus lenvatinib or abemaciclib NCT05774899 (PCD 2027-06-01); RGT-61159 NCT06462183 (Phase 1, active not recruiting, PCD 2027-12, 105 est.; includes a randomized two-dose optimization cohort and a lenvatinib combination arm); REM-422 NCT06118086 (Phase 1/2 ARIA, recruiting, PCD 2027-09-30, 125 est.); Emi-Le NCT05377996 (Phase 1/2, sponsor listed as Day One Biopharmaceuticals, PCD 2027-02, 360 est.); puxitatug samrotecan NCT07162480 (MD Anderson, PCD 2029-12-31, 28 est.); sacituzumab tirumotecan NCT07521670 (Singapore, not yet recrui

Brief source A3

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06891560

Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT06891560

Registry NCT06891560

Phase Phase 2

Status Recruiting

Enrollment 34

Start 2025-03-31

Primary completion 2027-03

Study completion 2027-03

Catalyst Primary completion. 03.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.